NASDAQ: THTX - Theratechnologies Inc.

Yield per half year: +110.08%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Theratechnologies Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Theratechnologies Inc.

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients.

more details
Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; and TH1902, which is in Phase 1 clinical trials for the treatment of various solid tumors, including HR+ breast cancer, triple negative breast cancer, ovarian cancer, endometrial cancer, melanoma, thyroid cancer, small cell lung cancer, and prostate cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2016-01-04
ISIN CA88338H1001
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.theratech.com
Цена ао 1.86
Change price per day: +5.45% (2.57)
Change price per week: +74.84% (1.55)
Change price per month: +72.06% (1.575)
Change price per 3 month: +57.56% (1.72)
Change price per half year: +110.08% (1.29)
Change price per year: +108.46% (1.3)
Change price per 3 year: +12.92% (2.4)
Change price per 5 year: +89.51% (1.43)
Change price per year to date: +63.25% (1.66)
All parameters

Underestimation

Title Value Grade
P/S 0.6898 10
P/BV -2.34 0
P/E 0 0
EV/EBITDA 14.38 7
Total: 3.63

Efficiency

Title Value Grade
ROA, % -12.67 0
ROE, % 36 9
Total: 2

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA 6.63 0
Total: 5.8

Growth impulse

Title Value Grade
Yield Revenue, % 29.9 4
Yield Ebitda, % -174.77 0
Yield EPS, % -42.84 0
Total: 0.8
More

Institutions Volume Share, %
Nantahala Capital Management, LLC 5364456 11.67
Soleus Capital Management, L.P. 4801376 10.44
AIGH Capital Management LLC 3719302 8.09
Morgan Stanley 2259400 4.91
Worth Venture Partners, LLC 906557 1.97
Osaic Holdings Inc 128054 0.28
National Bank of Canada/FI 113378 0.25
Cyndeo Wealth Partners, LLC 104120 0.23
Stifel Financial Corporation 69058 0.15
Wealthspire Advisors, LLC 51250 0.11



Head Job title Payment Year of birth
Mr. Paul Lévesque President, CEO & Director 1.18M 1964 (61 year)
Mr. Philippe Dubuc M.B.A., MBA Senior VP & CFO 432.31k 1967 (58 years)
Mr. Jocelyn Lafond L.L.M., LL.B. General Counsel & Corporate Secretary 316.29k 1968 (57 years)
Dr. Christian Marsolais Ph.D. Senior VP & Chief Medical Officer 434.61k 1963 (62 years)
Mr. John Leasure Global Commercial Officer 420.91k 1965 (60 years)
Hon. Andre Dupras M.Sc. Vice President of Human Resources N/A 1964 (61 year)

Address: Canada, Montreal. QC HA T, 2015 Peel Street - open in Google maps, open in Yandex maps
Website: https://www.theratech.com